Search: onr:"swepub:oai:lup.lub.lu.se:f5d1fc31-cd55-4ab0-9c25-297750abb9a2" >
Impact of different...
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
- Article/chapterEnglish2007
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:f5d1fc31-cd55-4ab0-9c25-297750abb9a2
-
https://lup.lub.lu.se/record/675200URI
-
https://doi.org/10.1111/j.1365-2516.2006.01400.xDOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
In order to describe the haemostatic role of a variation in inhibitor reactivity with different factor VIII (FVIII) concentrates, we have compared inhibitor titres against a panel of FVIII concentrates and correlated titre with the capacity to inhibit thrombin generation. Three plasma-derived concentrates were tested in vitro in mixing experiments with inhibitor plasmas from 11 patients with severe haemophilia A: Fanhdi, which contains von Willebrand factor (VWF) with a final ratio of approximately 1:1 (VWF IU per IU FVIII:Q; Haemate-P with a ratio of 2.5:1 and Hemofil-M containing only trace amounts of VWF. In addition, the recombinant FVIII concentrate Kogenate Bayer containing no VWF was included. Inhibitor titres and the capacity to generate thrombin were measured. A statistically significant difference in measured titres was found with the highest titres recorded against Hemofil-M. The inhibitor titres needed to inhibit 50% maximum thrombin generation were the lowest for Kogenate Bayer and the highest and similar for Fanhdi and Haemate-P with intermediate titres needed for inhibition of Hemofil-M. In this study, the thrombin generation assay provides additional indications for the role of VWF in the treatment of patients with inhibitors. The VWF-containing concentrates Fanhdi and Haemate-P, added to FVIII-deficient plasma with the presence of inhibitor, generate more thrombin than do the purified concentrates Hemofil-M and Kogenate Bayer.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Astermark, JanLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-jas
(author)
-
Ekman, MajLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-mek
(author)
-
Franchini, M.
(author)
-
Midi, G. C.
(author)
-
Lippi, G.
(author)
-
Poli, G.
(author)
-
Berntorp, ErikLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups(Swepub:lu)medf-ebe
(author)
-
Klinisk koagulationsmedicin, MalmöForskargrupper vid Lunds universitet
(creator_code:org_t)
Related titles
-
In:Haemophilia: Wiley13:1, s. 51-561351-82161365-2516
Internet link
Find in a library
To the university's database